Behrad Derakhshan net worth and biography

Behrad Derakhshan Biography and Net Worth

Chief Business Officer of Edgewise Therapeutics

Behrad Derakhshan, Ph.D. has served as Chief Business Officer since September 2020 and leads Edgewise’s efforts in strategic planning, business development, capital formation, investor relations, commercial and competitive intelligence. Prior to joining Edgewise, Dr. Derakhshan was Chief Business Officer at VectivBio after having served as the Head of Business Development at Therachon, until its acquisition by Pfizer Inc. in 2019 for $810 million. Prior to Therachon, Dr. Derakhshan was responsible for Business Development and Strategic Evaluation at Alexion. Earlier in his career, Dr. Derakhshan worked in management consulting with a focus on rare disease drug development. Dr. Derakhshan serves on the board of Innoskel, a private biotechnology company developing therapies for rare bone diseases. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK.

What is Behrad Derakhshan's net worth?: The estimated net worth of Behrad Derakhshan is at least $494.91 thousand as of May 2nd, 2024. Dr. Derakhshan owns 13,422 shares of Edgewise Therapeutics stock worth more than $494,909 as of June 19th. This net worth estimate does not reflect any other assets that Dr. Derakhshan may own. Learn More about Behrad Derakhshan's net worth.
How do I contact Behrad Derakhshan?: The corporate mailing address for Dr. Derakhshan and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Behrad Derakhshan's contact information.
Has Behrad Derakhshan been buying or selling shares of Edgewise Therapeutics?: Behrad Derakhshan has not been actively trading shares of Edgewise Therapeutics in the last ninety days. Most recently, Behrad Derakhshan sold 1,718 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $18.91, for a transaction totalling $32,487.38. Following the completion of the sale, the insider now directly owns 13,422 shares of the company's stock, valued at $253,810.02. Learn More on Behrad Derakhshan's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Badreddin Edris (Director and Co-Founder), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 1 times. They purchased a total of 10,700 shares worth more than $199,448.00. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 415,630 shares worth more than $10,207,497.29. The most recent insider tranaction occured on May, 5th when CMO Joanne M Donovan sold 50,000 shares worth more than $1,928,500.00. Insiders at Edgewise Therapeutics own 21.3% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 5/5/2026.

Behrad Derakhshan Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2024	Sell	1,718	$18.91	$32,487.38	13,422
2/8/2024	Sell	4,600	$20.01	$92,046.00	7,020
5/2/2023	Sell	1,747	$8.90	$15,548.30	7,020

Behrad Derakhshan Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $36.87

$35.39

$37.14

50 Day Range

MA: $33.96

$30.45

$40.26

2 Week Range

Now: $36.87

$12.15

$40.76

Volume

2,007,459 shs

Average Volume

1,828,253 shs

Market Capitalization

$3.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27